Endless possibilities in saving lives
RetroMAD1®, the world's first antiviral protein, saves cats suffering from feline leukemia, a disease once thought incurable
By: Biovalence Technologies
Mr. UNG, the co-inventor of RetroMAD1 and principal author of the research article, said, "In the published trial, we stopped observation of the non-RetroMAD1-
FeLV is a disease of veterinary importance, almost always fatal within 12 months after clinical signs appear. In a report by statista.com, the global population of client-owned cats is estimated at 373,000,000 in 2018. The worldwide prevalence of feline leukemia is difficult to estimate. In developing economies like Brazil and China, the prevalence is estimated to be as high as 25% in client-owned cats.
Dr. Alex NG, the Chairman and CEO of Biovalence Technologies, remarked, "In over 100 cases of cats suffering from FeLV presented by their owners from Germany, Malaysia, Singapore, South Africa and the U.S. that received RetroMAD1 treatment, the lives of all these cats improved so dramatically after several weeks that the owners could not believe what they witnessed. Their cats continue to live well, free from suffering, and the owners willingly share their experiences. Without a doubt, RetroMAD1 saves lives".
Treatment against FeLV has been, up to now, symptomatic and palliative. With RetroMAD1, there is now hope of a real antidotal treatment for veterinarians and cat owners worldwide to prolong and improve the lives of their cats suffering from this disease that was once thought to be incurable.